Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Causeway Therapeutics Limited manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This action is located in 1 distinct art unit, suggesting that the company's current intellectual property efforts are focused on a specific technical niche within the pharmaceutical sector.
The prosecution involves 1 distinct examiner, VYAS, KEYUR ANILKUMAR. As the busiest examiner for the portfolio, VYAS, KEYUR ANILKUMAR is currently overseeing 1 busiest examiner pending office action. This 1 pending action represents the entirety of the company's active workload at the patent office, which indicates a streamlined prosecution process.
Practitioners can focus their efforts on the 1 pending office action and the specific examination history of VYAS, KEYUR ANILKUMAR. Because the portfolio is concentrated in 1 distinct art unit with 1 distinct examiner, the firm can develop a targeted strategy. This approach allows for a deep focus on the technical requirements of the Biotechnology & Pharmaceuticals area as they apply to the 1 pending office action currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033322 | MICRORNA-29 COMPOUNDS, COMPOSITIONS AND USES IN THERAPY | VYAS, KEYUR ANILKUMAR | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033322 | MICRORNA-29 COMPOUNDS, COMPOSITIONS AND USES IN THERAPY | VYAS, KEYUR ANILKUMAR | 1637 | §103§112DP | Non-Final OA | — | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCauseway Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Keyur Anilkumar Vyas has the most, with 1 of Causeway Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
